-
公开(公告)号：US11021455B2
公开(公告)日：2021-06-01
申请号：US16309710
申请日：2017-06-13
发明人： Byeong Moon Kim , Bong Kyu Choi , Jae Hyun Sim , Eun Ju Ryu , Ji Su Park , Il Hak Bae
IPC分类号： C07D307/88 , A61P31/04 , C07D209/46 , C07D307/93
摘要： The present invention relates to a novel brominated furanone derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient, wherein the novel brominated furanone derivative or a pharmaceutically acceptable 5 salt thereof according to the present invention exhibits a quorum sensing inhibitory activity of bacteria and also can effectively inhibit the formation of biofilm of bacteria, and thus can be used as a pharmaceutical composition containing the same as an active ingredient, thereby having an effect of being useful, 10 for example, for periodontal diseases such as gingivitis and periodontitis, oral diseases, and the like.
-
公开(公告)号：US20210054038A1
公开(公告)日：2021-02-25
申请号：US16979078
申请日：2019-03-05
发明人： Byeong Moon Kim , Yan Lee , Eun Joung Choi , Dongwook Jung
IPC分类号： C07K14/505 , C07K19/00 , A61K47/60
摘要： Disclosed are a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing same as an active ingredient. The method for preparing a biomaterial to which a compound represented by chemical formula 2 is coupled, of the present invention, allows the compound represented by chemical formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.
-
公开(公告)号：US11261175B2
公开(公告)日：2022-03-01
申请号：US16633382
申请日：2018-09-20
发明人： Byeong Moon Kim , Sung Key Jang , Young Su You , Il Hak Bae , Heejo Moon , Byeong Wook Kim , Hee Sun Kim , Jaegon Mun
IPC分类号： C07D403/12 , A23L33/10 , A61P31/14 , C07D403/14 , C07D413/14 , C07D491/113 , C07D519/00
摘要： The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treating HCV-related disease. A fluorene derivative according to the present invention is identified to exhibit an antiviral performance against not only HCV, but also highly against HCV mutants, particularly double mutants and thus can be used in a pharmaceutical composition for prevention or treatment of HCV-caused liver disease, such as acute hepatitis C, chronic hepatitis C, liver cirrhosis, hepatocellular cancer, etc., particularly, liver disease caused by mutants of HCV. The derivative can be useful in a pharmaceutical composition for prevention or treatment of HCV-related liver disease by which the problem of resistant mutation against conventional therapeutic agents is solved.
-
公开(公告)号：US20200231573A1
公开(公告)日：2020-07-23
申请号：US16633382
申请日：2018-09-20
发明人： Byeong Moon Kim , Sung Key Jang , Su Young You , Il Hak Bae , Heejo Moon , Byeong Wook Kim , Hee Sun Kim , Jaegon Mun
IPC分类号： C07D403/12 , C07D403/14 , C07D491/113 , C07D519/00 , C07D413/14 , A23L33/10 , A61P31/14
摘要： The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treating HCV-related disease. A fluorene derivative according to the present invention is identified to exhibit an antiviral performance against not only HCV, but also highly against HCV mutants, particularly double mutants and thus can be used in a pharmaceutical composition for prevention or treatment of HCV-caused liver disease, such as acute hepatitis C, chronic hepatitis C, liver cirrhosis, hepatocellular cancer, etc., particularly, liver disease caused by mutants of HCV. The derivative can be useful in a pharmaceutical composition for prevention or treatment of HCV-related liver disease by which the problem of resistant mutation against conventional therapeutic agents is solved.
-
公开(公告)号：US20190224222A1
公开(公告)日：2019-07-25
申请号：US16364422
申请日：2019-03-26
申请人： Seoul National University R&DB Foundation , Foundation of Soongsil University-Industry Cooperation
发明人： Bong Kyu CHOI , Eun Ju Ryu , Jae Hyun Sim , Byeong Moon Kim , Julian Lee , Jun Sim
IPC分类号： A61K31/7004 , A61P31/04
摘要： Provided are a use of D-galactose in inhibition of quorum sensing and/or in prevention and/or treatment of oral bacterial diseases; in particular, a composition for inhibiting quorum sensing and a composition for preventing and/or treating oral bacterial diseases, the composition comprising D-galactose, and a method of inhibiting quorum sensing and a method of preventing and/or treating oral bacterial diseases, the method comprising administering D-galactose.
-
公开(公告)号：US20160082023A1
公开(公告)日：2016-03-24
申请号：US14860813
申请日：2015-09-22
申请人： Seoul National University R&DB Foundation , Foundation of Soongsil University-Industry Cooperation
发明人： Bong Kyu Choi , Eun Ju Ryu , Jae Hyun Sim , Byeong Moon Kim , Julian Lee , Jun Sim
IPC分类号： A61K31/7004
CPC分类号： A61K31/7004 , Y02A50/481
摘要： Provided are a use of D-galactose in inhibition of quorum sensing and/or in prevention and/or treatment of oral bacterial diseases; in particular, a composition for inhibiting quorum sensing and a composition for preventing and/or treating oral bacterial diseases, the composition comprising D-galactose, and a method of inhibiting quorum sensing and a method of preventing and/or treating oral bacterial diseases, the method comprising administering D-galactose.
摘要翻译： 提供D-半乳糖在抑制群体感应和/或预防和/或治疗口腔细菌性疾病中的用途; 特别是用于抑制群体感应的组合物和用于预防和/或治疗口腔细菌性疾病的组合物，所述组合物包含D-半乳糖，以及抑制群体感测的方法以及预防和/或治疗口腔细菌性疾病的方法， 方法包括给予D-半乳糖。
-
公开(公告)号：US12122812B2
公开(公告)日：2024-10-22
申请号：US16979078
申请日：2019-03-05
发明人： Byeong Moon Kim , Yan Lee , Eun Joung Choi , Dongwook Jung
IPC分类号： C07K1/13 , A61K47/60 , C07K14/505 , C07K19/00 , A61K38/00
CPC分类号： C07K14/505 , A61K47/60 , C07K19/00 , C12Y304/21001 , A61K38/00
摘要： Disclosed are a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing same as an active ingredient. The method for preparing a biomaterial to which a compound represented by chemical formula 2 is coupled, of the present invention, allows the compound represented by chemical formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.
-
公开(公告)号：US10292993B2
公开(公告)日：2019-05-21
申请号：US14860813
申请日：2015-09-22
申请人： Seoul National University R&DB Foundation , Foundation of Soongsil University—Industry Cooperation
发明人： Bong Kyu Choi , Eun Ju Ryu , Jae Hyun Sim , Byeong Moon Kim , Julian Lee , Jun Sim
IPC分类号： A61K31/7004 , A61P31/04
摘要： Provided are a use of D-galactose in inhibition of quorum sensing and/or in prevention and/or treatment of oral bacterial diseases; in particular, a composition for inhibiting quorum sensing and a composition for preventing and/or treating oral bacterial diseases, the composition comprising D-galactose, and a method of inhibiting quorum sensing and a method of preventing and/or treating oral bacterial diseases, the method comprising administering D-galactose.
-
9.发明申请BENZIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING BENZIDINE DERIVATIVE FOR TREATING LIVER DISEASE CAUSED BY HEPATITIS C VIRUS 有权苯肼衍生物，其制备方法和含有苯肼衍生物的药物组合物用于治疗由乙型肝炎病毒引起的肝病公开(公告)号：US20160031810A1
公开(公告)日：2016-02-04
申请号：US14884356
申请日：2015-10-15
发明人： Sung Key Jang , Byeong Moon Kim , IL Hak Bae , Jin Kyu Choi , Sun Ju Keum , Seung Gi Lee , Hee Sun Kim
IPC分类号： C07D207/16 , A23L1/30 , C07D405/14 , C07K5/065 , C07K5/062
CPC分类号： C07D207/16 , A23L33/10 , A23V2002/00 , C07D207/24 , C07D211/60 , C07D277/06 , C07D405/14 , C07K5/06026 , C07K5/06034 , C07K5/06078
摘要： The disclosed compounds have antiviral activity against C-type virus, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating liver disease caused by hepatitis C virus. The benzidine derivative according to the present invention has excellent antiviral activity against hepatitis C virus and exhibits excellent medicinal activity in the living body, and thus the pharmaceutical composition containing the same as an active ingredient can be useful as a pharmaceutical composition for preventing or treating liver disease, such as acute hepatitis C, chronic hepatitis C, cirrhosis, or hepatocellular carcinoma, caused by C-type virus.
摘要翻译： 所公开的化合物对C型病毒具有抗病毒活性，其旋光异构体，其药学上可接受的盐，其制备方法和含有该组合物的预防或治疗由肝炎引起的肝病的活性成分的药物组合物 C病毒。 根据本发明的联苯胺衍生物对丙型肝炎病毒具有优异的抗病毒活性，并且在活体中表现出优异的药物活性，因此含有活性成分的药物组合物可用作预防或治疗肝脏的药物组合物 C型病毒引起的急性丙型肝炎，慢性丙型肝炎，肝硬化或肝细胞癌等疾病。
-
公开(公告)号：US09598362B2
公开(公告)日：2017-03-21
申请号：US14884356
申请日：2015-10-15
发明人： Sung Key Jang , Byeong Moon Kim , Il Hak Bae , Jin Kyu Choi , Sun Ju Keum , Seung Gi Lee , Hee Sun Kim
IPC分类号： C07D207/16 , C07D207/24 , C07D277/06 , C07D211/60 , C07K5/062 , C07K5/065 , C07D405/14
CPC分类号： C07D207/16 , A23L33/10 , A23V2002/00 , C07D207/24 , C07D211/60 , C07D277/06 , C07D405/14 , C07K5/06026 , C07K5/06034 , C07K5/06078
摘要： The disclosed compounds have antiviral activity against C-type virus, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating liver disease caused by hepatitis C virus. The benzidine derivative according to the present invention has excellent antiviral activity against hepatitis C virus and exhibits excellent medicinal activity in the living body, and thus the pharmaceutical composition containing the same as an active ingredient can be useful as a pharmaceutical composition for preventing or treating liver disease, such as acute hepatitis C, chronic hepatitis C, cirrhosis, or hepatocellular carcinoma, caused by C-type virus.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.028 秒)
